Galvani Bioelectronics is a Stevenage, United Kingdom-based[5] bioelectronics R&D company.
History
It was founded by Alphabet Inc. subsidiary Verily Life Sciences and British pharmaceutical company GlaxoSmithKline (GSK) in November 2016.[1][2] The partnership to form the company was announced on 1 August 2016.[4]
Verily has a 45% equity interest, while GSK has a 55% equity interest, making GSK the effective owner.[4] The initial agreed upon investment between the two companies is up to £540 million over a period of seven years[4][6] and will be used "to develop prototype devices aimed at controlling a variety of chronic conditions."[7] Additionally, both companies agreed to contribute their existing intellectual property rights.
In November 2021, a team of laparoscopic surgeons successfully completed the first implantation of a Galvani device in a patient. [8]
External links
References
- Galvani Bioelectronics Website Galvani Bioelectronics, retrieved 24 December 2016^
- Galvani Bioelectronics Verily Life Sciences website, retrieved 24 December 2016^
- Kristoffer Famm Ph.D. - Galvani Bioelectronics Galvani Bioelectronics, retrieved 25 December 2016^
- James Temperton. GSK and Google just created a £540m bioelectronic health firm Wired, 1 August 2016, retrieved 24 December 2016^
- Julia Kollewe. Electroceuticals: the 'bonkers' gamble that could pay off for GlaxoSmithKline the Guardian, 2017-08-28, retrieved 2018-08-03^
- Bioelectric Medicine Market Focusing Long-Term Professional Industry and Making New Commitments to the Sustainable Future Worldanalytics24.com, 23 January 2019, retrieved 2019-01-31^
- Galvani Bioelectronics FierceBiotech, retrieved 2020-07-13^
- Verily Life Sciences verily.com, retrieved 2017-02-15^